Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Posts $3.9B Cash, $209M Buyback, and Genevant's $950M Moderna Windfall

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$35.1
Mkt Cap
$24.995B
52W Low
$10.9
52W High
$37
52W Position info
222% above low
Off High info
5.1% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $10.9.

Summary

Roivant's Q1 update packs several material positives. Cash stands at $3.9 billion, boosted by a $950 million initial payment from the Moderna patent settlement received in July. The company bought back $208.7 million in shares during the quarter, signaling confidence. The brepocitinib launch in dermatomyositis is on track for end of September, and enrollment has started in a Phase 3 cutaneous sarcoidosis trial. Multiple topline readouts are due in H2 2026 across brepocitinib, IMVT-1402, and mosliciguat. This follows a transformative fiscal 2026 and sets up a catalyst-heavy second half. The cash runway extends to profitability, reducing financing risk.

At the time of this announcement, ROIV was trading at $35.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25B. The 52-week trading range was $10.90 to $37.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $38.68 info
Change: -$2.69 (-7%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $38.68 info
Change: -$2.32 (-6%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $38.68 info
Change: -$1.71 (-4%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $38.68 info
Change: +$2.48 (+7%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $38.68 info
Change: +$2.08 (+6%) info
Market Cap: $28.008B info